Randomized Trialhigh evidence
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.
The New England journal of medicine·May 25, 2026·PMID 42187087
Why it mattersThis represents a novel, potentially durable approach to LDL lowering via a one-time genetic intervention, which could address adherence and access barriers associated with chronic therapies like PCSK9 monoclonal antibodies or statins.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled